芪苈强心胶囊对PCI 术后患者心肌损伤及血管内皮功能的影响
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R541

基金项目:


Effect of Qili Qiangxin Capsules on Myocardial Injury and Vascular Endothelial Function in Patients After PCI
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察芪苈强心胶囊对经皮冠状动脉介入(PCI) 术后患者心肌损伤和血管内皮功能的影响。方法:选取70 例行PCI 治疗的患者,随机分为观察组和对照组,每组35 例。对照组术后给予常规西药治疗,观察组在对照组基础上给予芪苈强心胶囊治疗。2 组均治疗6 个月。比较2 组治疗前后心功能指标、心肌损伤标志物及血管内皮功能标志物水平;比较2 组不良反应发生率。结果:治疗后,2 组左室射血分数(LVEF) 均较治疗前增大(P<0.05),左室舒张末期内径(LVEDD) 及左室内径(LVD) 均较治疗前缩小(P<0.05);观察组LVEF 大于对照组(P<0.05),LVEDD 及LVD 均小于对照组(P<0.05)。治疗后,2 组心肌肌钙蛋白I(cTnI)、肌酸激酶同工酶(CK-MB) 水平均较治疗前升高(P<0.05),观察组cTnI、CK-MB 水平均低于对照组(P<0.05)。治疗后,2 组一氧化氮(NO) 水平及内皮依赖性血管舒张功能(FMD)、非内皮依赖性血管舒张功能(NMD) 均较治疗前升高(P<0.05),ET-1 水平均较治疗前降低(P<0.05);观察组NO 水平及FMD、NMD 均高于对照组(P<0.05),ET-1 水平低于对照组(P<0.05)。观察组不良反应发生率为8.57%,低于对照组的37.14% (P<0.05)。结论:芪苈强心胶囊可有效改善PCI 术后患者的心功能,缓解其心肌损伤,提升其血管内皮功能,降低不良反应发生率。

    Abstract:

    Abstract: Objective: To observe the effect of Qili Qiangxin capsules on myocardial injury and vascular endothelial function in patients after percutaneous coronary intervention(PCI). Methods:A total of 70 cases of patients undergoing PCI treatment were randomly divided into the observation group and the control group,35 cases in each group. The control group was treated with conventional western medicine, and the observation group was additionally treated with Qili Qiangxin capsules based on the treatment of the control group. Both groups were treated for six months. The levels of heart function indexes, myocardial injury markers and vascular endothelial function markers before and after treatment as well as the incidence of adverse reactions in the two groups were compared. Results:After treatment,left ventricular ejection fraction (LVEF) in the two groups was increased when compared with that before treatment(P<0.05), and left ventricular enddiastolic diameter(LVEDD) and left ventricular diameter(LVD) were decreased(P<0.05); LVEF in the observation group was higher than that in the control group(P<0.05), and LVEDD and LVD were lower(P<0.05). After treatment, the levels of cardiac troponin I(cTnI) and creatine kinase-MB(CK-MB) in the two groups were increased when compared with those before treatment(P<0.05),and the levels of cTnI and CK-MB in the observation group were lower than those in the control group (P<0.05). After treatment,nitric oxide(NO) levels,flow-mediated dilation(FMD) and nitroglycerin-mediated dilation(NMD) in the two groups were increased when compared with those before treatment(P<0.05),and ET-1 levels were decreased(P< 0.05);NO levels,FMD and NMD in the observation group were higher than those in the control group(P<0.05),and ET-1 level was lower(P<0.05). The incidence of adverse reactions was 8.57% in the observation group,lower than that of 37.14% in the control group(P<0.05). Conclusion: Qili Qiangxin capsules for patients after PCI can effectively improve their heart function,alleviate their myocardial injury,improve their vascular endothelial function,and reduce the incidence of adverse reactions.

    参考文献
    相似文献
    引证文献
引用本文

张智敏,黄咏梅.芪苈强心胶囊对PCI 术后患者心肌损伤及血管内皮功能的影响[J].新中医,2021,53(14):93-96

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-07-24
  • 出版日期:
文章二维码